Related NSANY Disappointing March Auto Sales Spell Trouble For 2016 Targets; Autos React Auto Industry In Largest Credit Bubble Ever, Morgan Stanley's Jonas Warns German government expected to give EVs a tax break (Seeking Alpha) Related NSANF Crossover, Alternative Car Sales Helped Boost May Auto Industry Figures Which is the Better Investment: Honda vs. Toyota
Shares of Japan’s MITSUBISHI MOTOR C NPV (OTC: MMTOF) (OTC: MMTOY) plunged to record lows on a mileage cheating scandal, leaving the firm vulnerable to heavy compensation and fines. The shares nosedived for the second straight day after the automaker admitted it had overstated the fuel efficiency of 625,000 cars.
5 Best Life Sciences Stocks To Watch For 2017: Energy XXI Ltd.(EXXI)
Energy XXI Ltd engages in the acquisition, exploration, development, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico. As of June 30, 2015, the company had net proved reserves of 183.5 million barrels of oil equivalent. It operated or had an interest in 567 gross producing wells on 388,199 net developed acres, including interests in 52 producing fields. The company was founded in 2005 and is based in Houston, Texas.
- [By Lisa Levin]
Shares of Energy XXI Ltd (NASDAQ: EXXI) were down 72 percent to $0.181 after the company announced that it and some of its subsidiaries have entered into a Restructuring Support Agreement (RSA) with holders of more than 63 percent of its secured second lien 11.0 percent notes. Energy XXI added that in order to implement the terms of the RSA, it has commenced cases under Chapter 11 of the Bankruptcy Code.
5 Best Life Sciences Stocks To Watch For 2017: Omeros Corporation(OMER)
Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
The Company’s pipeline includes clinical-stage development programs focused on complement-related thrombotic microangiopathies (TMAs); complement-mediated glomerulopathies; Huntington’s disease and cognitive impairment; addictive and compulsive disorders, and problems associated with urologic surgical procedures. In addition, it has a group of preclinical programs and over two additional platforms: one capable of unlocking new G protein-coupled receptor (GPCR) drug targets and the other used to generate antibodies. OMS103 is the Company’s PharmacoSurgery product candidate, which is developed for use during all arthroscopic procedures, including knee and shoulder arthroscopy, and completed Phase III trials in patients undergoing arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. OMS103 is a combination of anti-inflammatory/analgesic active pharma ceutical ingredients (APIs), specifically amitriptyline, ket! oprofen and oxymetazoline, and designed to provide a multimodal approach to block preemptively the inflammatory cascade induced by arthroscopy. OMS103 is delivered directly to the joint throughout arthroscopy and is designed to act simultaneously at multiple distinct targets to block preemptively the inflammatory cascade induced by arthroscopic surgery.
Omidria is approved by the FDA for use during cataract surgery or IOL replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain and is approved in all European Union (EU) member states for use during cataract surgery and other IOL replacement procedures to maintain mydriasis (pupil dilation), to prevent miosis and to reduce postoperative eye pain. Omidria is a drug product containing two APIs: ketorolac, an anti-inflammatory agent, and phenylephrine, a mydriatic, or pupil dilating, agent. These procedures are performed to replace a lens opacified by a cataract or to correct a refractive error. Omidria is added to standard irrigation solution used during cataract and lens replacement surgery and is delivered intracamerally, or within the anterior chamber of the eye, to the site of the surgical trauma throughout the procedure.
The Company’s clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (OMS405)-Addiction, and OMS201-Urology. The MASP-2 is a pro-inflammatory protein target involved in activation of the complement system. OMS721 is its lead human monoclonal antibody targeting MASP-2. OMS721 has received Orphan Drug designation for the prevention (inhibition) of complement-mediated TMAs, and Fast Track designation for the treatment of patients with Atypical Hemolytic Uremic Syndrome (aHUS). Phosphodiesterase 10 ( PDE10) is an enzyme that is expressed in areas of the brain ! linked to! diseases that affect cognition, including Huntington’s disease and schizophrenia. OMS824 has received Orphan Drug designation for the treatment of Huntington’s disease and Fast Track designation for the treatment of cognitive impairment in patients with Huntington’s disease. OMS824 is in a Phase II clinical program for the treatment of Huntington’s disease and a Phase II clinical program evaluating OMS824 for the treatment of schizophrenia.
The peroxisome proliferator-activated receptor gamma program is developing compositions that include peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. It has completed two Phase II clinical trials related to its peroxisome proliferator-activated receptor gamma program. OMS201 is its PharmacoSurgery product candidate designed for use during urological procedures, including ureterscopy for removal of u reteral or renal stones. OMS201 is a combination of ketoprofen, an anti-inflammatory API, and nifedipine, a smooth muscle relaxant API. It has completed a Phase I/Phase II clinical trial.
The Company’s preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform. The PDE7 program is based on its discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson’s disease. In its plasmin program, the Company is advancing antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma, as well as for other hyperfibrinolytic states. As part of its MASP program, it has identified MASP-3.
The Company is condu! cting med! icinal chemistry to optimize compounds against GPR17, a GPCR that is linked to myelin formation. It is conducting medicinal chemistry to optimize compounds against GPR101, a GPCR that is linked to appetite and eating disorders. It is conducting medicinal chemistry to optimize compounds against GPR151, a GPCR that is linked to neuropathic pain and cognitive disorders. It is conducting medicinal chemistry to optimize compounds against GPR161, a GPCR that is linked to triple negative breast cancer (TNBC) and sarcomas. It is conducting medicinal chemistry to optimize compounds against GPR174, a GPCR that is linked to autoimmunity. It is conducting medicinal chemistry to optimize compounds against GPR183, a GPCR that is linked to osteoporosis and Epstein-Barr virus (EBV) infections, and associated diseases. The ex vivo platform is for the discovery of monoclonal antibodies, which utilizes a chicken B-cell lymphoma cell line.
The Company competes with The Nordic Group .
- [By Monica Gerson]
Omeros (NASDAQ: OMER) shares fell 2.80% to $8.32 in the pre-market trading. Omeros shares have dropped 9.80% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.
Top 10 Specialty Retail Companies To Buy Right Now: China Automotive Systems, Inc.(CAAS)
China Automotive Systems, Inc., (China Automotive), incorporated on June 23, 1999, is a holding company. The Company, through its subsidiary, Great Genesis Holdings Limited (Genesis), owns interests in over eight Sino-joint ventures and over five subsidiaries in the People’s Republic of China (PRC), which manufacture power steering systems and/or related products for various segments of the automobile industry. Genesis also owns interests in a Brazil-based trading company, which engages mainly in the import and sales of automotive parts in Brazil. Henglong USA Corporation (HLUSA), which is a subsidiary of the Company, engages in marketing of automotive parts in North America, and provides after sales service and research and development support. The Company’s geographical segments include the United States, China and other foreign countries.
The Company’s subsidiary, Shenyang Jinbei Henglong Automotive Steering System Co., Ltd., focuses on power steering parts for light duty vehicles; Jingzhou Henglong Automotive Parts Co., Ltd. engages in the production of rack and pinion power steering gears for cars and light-duty vehicles; Shashi Jiulong Power Steering Gears Co., Ltd. mainly engages in the production of integral power steering gears for heavy-duty vehicles; Universal Sensor Application Inc. engages in the production and sales of sensor modules; Hubei Henglong Automotive System Group Co., Ltd engages in the production and sales of automotive steering systems; Chongqing Henglong Hongyan Automotive System Co., Ltd designs, develops and manufactures both hydraulic and electric power steering systems and parts; CAAS Brazil’s Imports And Trade In Automotive Parts Ltd. engages in the design, development and manufacture of both hydraulic and electric power steering systems and parts, and Fujian Qiaolong Special Purpose Vehicle Co., Ltd. manufactures and distributes drainage and rescue vehicles with mass flow, drainage vehicles with v ertical downhole operation, crawler-type mobile pump station! s, high-altitude water supply and discharge drainage vehicles, long-range control crawler-type mobile pump stations and other vehicles. Its Wuhan Chuguanjie Automotive Science and Technology Ltd. engages in research and development, manufacture and sales of automobile electronic systems and parts.
The Company competes with SAIC, ZF Germany, First Auto Group, Koyo Company and Nexteer.
- [By Monica Gerson]
China Automotive Systems, Inc. (NASDAQ: CAAS) is projected to post its quarterly earnings at $0.20 per share on revenue of $108.22 million.
Affimed NV (NASDAQ: AFMD) is projected to post a quarterly loss at $0.18 per share on revenue of $1.71 million.
5 Best Life Sciences Stocks To Watch For 2017: Net 1 UEPS Technologies, Inc.(UEPS)
Net 1 UEPS Technologies, Inc. provides payment solutions and transaction processing services for various industries in South Africa, South Korea, and internationally. The company develops and markets transaction processing solutions that comprise its smart card-based alternative payment system for the unbanked and under-banked populations of developing economies, and for mobile transaction channels. It operates through three segments: South African Transaction Processing, International Transaction Processing, and Financial Inclusion and Applied Technologies. The South African Transaction Processing segment provides welfare benefit distribution services to the South African government and transaction processing for retailers, utilities, medical-related claim service customers, and banks. The International Transaction Processing segment offers payment processing services to merchants and card issuers through its value-added netw ork. The Financial Inclusion and Applied Technologies segment provides short-term loans; and smart card accounts, as a fixed monthly fee per card. This segment also sells prepaid products comprising electricity and airtime, as well as hardware and software products; and offers life insurance products. Net 1 UEPS Technologies, Inc. was founded in 1989 and is headquartered in Johannesburg, South Africa.
- [By Javier Hasse]
Friday’s after-hours trading session did not see many stocks on the move. Shares of Net 1 UEPS Technologies Inc (NASDAQ: UEPS) were down almost 2.5 percent in what seemed like a correction of the 1.83 percent surge seen during the day.
5 Best Life Sciences Stocks To Watch For 2017: Google Inc.(GOOG)
Google Inc. maintains an index of Web sites and other online content for users, advertisers, and Google network members and other content providers. It offers AdWords, an auction-based advertising program; AdSense program, which enables Web sites that are part of the Google Network to deliver ads from its AdWords advertisers; Google Display, a display advertising network that comprises the videos, text, images, and other interactive ads; DoubleClick Ad Exchange, a real-time auction marketplace for the trading of display ad space; and YouTube that provides video, interactive, and other ad formats for advertisers. The company also provides Google Mobile that optimizes Google?s applications for mobile devices in browser and downloadable form; and enables advertisers to run search ad campaigns on mobile devices, as well as Google Local that provides local information on the Web; and Google Boost for small businesses to participate in the ads auction. In addition, it offers And roid, an open source mobile software platform; Google Chrome OS, an open source operating system; Google Chrome, a Web browser; Google TV, a platform for the consumers to use the television and the Internet on a single screen; and Google Books platform to discover, search, and consume content from printed books online. Further, the company provides Google Apps, a cloud computing suite of message and collaboration tools, which includes Gmail, Google Docs, Google Calendar, and Google Sites; Google Search Appliance that offers real-time search of business and intranet applications, and public Web sites; Google Site Search, a custom search engine; Google Commerce Search for online retail enterprises; Google Checkout to make online shopping and payments streamlined and secure; Google Maps Application Programming Interface; and Google Earth Enterprise, a firewall software solution for imagery and data visualization. Google Inc. was founded in 1998 and is headquartered in Mountain View, California.
- [By Jim Lowell, Partner and Chief Investment Strategist, Adviser Investments]
If you look at the kinds of holdings he has now—Google (GOOG), Apple (AAPL), Disney (DIS), Coca Cola (KO); these are hardly overlooked or unloved names, but when he bought them, he bought them on the cheap and they have certainly contributed handsomely to his significant outperformance.
- [By Paul Ausick]
The Hudl is aimed at the low end of the U.K. market. At the high end lives Apple Inc. (NASDAQ: AAPL) and its iPad mini, with a starting price of 拢269 ($430). Tescos Hudl uses the Android operating system from Google Inc. (NASDAQ: GOOG).
- [By Amber Hestla, Michael J. Carr]
Among its suppliers is Flextronics International (Nasdaq: FLEX), which offers a variety of engineering services and provides supply chain management. Other Flextronics customers include Hewlett-Packard (NYSE: HPQ), LG and Google's (Nasdaq: GOOG) Motorola Mobility.
- [By Gregory Ness]
The hybrid cloud is the next major opportunity for disruptive innovation, and companies like Amazon (AMZN), Google (GOOG), Microsoft and VMware (VMW) are well-poised to establish best of breed cloud services. Recent estimates peg investments in cloud infrastructure to now exceed $50B per year.